Furthermore, the present study has also demonstrated that LECT2 restoration either by recombinant protein supply or gene delivery is effective in perturbing the HCC progression in vitro and in vivo, advocating LECT2-based therapy may facilitate a novel CSCs-targeting therapy or serve as an adjuvant therapy in conjunction with current HCC therapies for HCC control. This evidence concerns the gene LECT2 and hepatocellular carcinoma.